Back to homepage

Nephrology and Urology

Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function

Authors: Christopher M Blanchette, Anthony P Nunes, Nancy D Lin, Kathleen M Mortimer, Joshua Noone, Krishna Tangirala, Stephen Johnston, Benjamin Gutierrez

Risk evaluation and mitigation strategies (REMS), as mandated by the FDA for medications with the potential for harm, are increasingly incorporating rigid protocols for patient evaluation, but little is known about compliance with these programs. This study assessed adherence to liver function test (LFT) requirements included in the REMS program for bosentan and the results suggest that the program may not have adequately guaranteed adherence to monthly monitoring of LFTs.

More

Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?

Authors: Eva Vivian, Chelsea Mannebach

In this article authors review recent studies and evaluate the benefits and risks of combination therapy with an angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB), or a direct renin inhibitor (DRI) to attenuate the progression of diabetic nephropathy.

More

Hemodynamic effect of avanafil and glyceryl trinitrate coadministration

Authors: Dennis Swearingen, Ajay Nehra, Susie Morelos and Craig A Peterson

In this study, investigators examined the magnitude and duration of the interactions (when coadministered with glyceryl trinitrate) of the latest phosphodiesterase type-5 inhibitor avanafil on systolic blood pressure and heart rate compared with sildenafil and placebo.

More